EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Initiation of GLP-1 Receptor Agonists Treatment after Bariatric Metabolic Surgery and Major Adverse Cardiac Events

Orna Reges, Wiessam Abu Ahmad, Noga Oz-Ramot, Erez Battat, Philip Greenland, Ronen Arbel, Yael Wolff Sagy, Gil Lavie, Dror Dicker

Obesity Facts · 20.05.2026 · 1-11

DOI: 10.1159/000551805 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity Facts, online erschienen am 20.05.2026. Verfasst von Orna Reges und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Systems Management, Ariel University, Ariel, Israel, ornar@ariel.ac.il. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Bariatric metabolic surgery (BMS) alone or glucagon-like peptide-1 receptor agonists (GLP-1RA) alone are known to reduce major adverse cardiovascular events (MACEs). However, the benefit for primary prevention of MACE with use of GLP-1RA treatment after BMS is unclear. This retrospective cohort study assessed the associations of post-BMS GLP-1RA treatment with first incidence of MACE/all-cause mortality, as well as with predicted cardiovascular (CVD) risk and body mass index (BMI) and hemoglobin-A1c (HbA1c) levels, among patients with obesity and diabetes.

Methods

Adults who initiated GLP-1RA post-BMS were compared with individuals who did not. Groups were matched based on age, sex, BMI, HbA1c, years since BMS, and the nearest-neighbor propensity score for the probability of receiving GLP-1RA. Follow-up began at GLP-1RA initiation and ended on December 31, 2023.

Results

The study population included 476 GLP-1RA initiators and 952 matched BMS-only patients (mean [SD] age: 48.7 [9.5] years; 1,046 [73.2%] women). GLP-1RA initiation after BMS was associated with reduction in BMI (−7.0%) and HbA1c (−13.0%) and higher diabetes remission (78.0% vs. 61.6%). Ten-year predicted CVD risk was similar between users and nonusers before treatment initiation (0.053%) but was significantly lower among users during follow-up (0.039% vs. 0.046%). During a mean (SD) follow-up of 1.4 (0.8) years (maximum ∼10.6 years), there were 12.7 per 1,000 person months (n = 17) and 10.6 per 1,000 person months (n = 7) new cases of MACE and all-cause mortality in the BMS-only and GLP-1RA post-BMS group, respectively. No overall statistically significant association was observed between initiation of GLP-1RA after BMS and MACE/all-cause mortality. However, significant interaction was observed with time since BMS (p = 0.04), with a lower risk of MACE/all-cause mortality as the time from BMS increased.

Conclusion

Initiation of GLP-1RAs after BMS was associated with lower BMI and HbA1c levels, higher diabetes remission, and reduced predicted CVD risk among patients with diabetes and obesity. Overall, GLP-1RA treatment after BMS did not further reduce the risk of MACE/all-cause mortality compared to BMS alone after a mean follow-up of 1.4 years. Given the observed time-dependent benefit of treatment after BMS, longer follow-up studies are needed to determine the optimal timing for initiation.

Schlagwörter

Stichwörter der Autor:innen

Bariatric surgeryDiabetesGlucagon-like peptide-1 receptor agonistsMajor adverse cardiovascular eventsObesity

Autor:innen und Institutionen

  • Department of Health Systems Management, Ariel University, Ariel, Israel, ornar@ariel.ac.il.
  • Branch of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel, ornar@ariel.ac.il.
  • Branch of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel.
  • Hadassah Braun School of Public Health and Community Medicine, Hebrew University, Jerusalem, Israel.
  • Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Maximizing Health Outcomes Research Lab, Sapir College;, Sderot, Israel.

Zitieren

APA

Reges, O., Abu Ahmad, W., Oz-Ramot, N., Battat, E., Greenland, P., Arbel, R., Wolff Sagy, Y., Lavie, G., & Dicker, D. (2026). Initiation of GLP-1 Receptor Agonists Treatment after Bariatric Metabolic Surgery and Major Adverse Cardiac Events. Obesity Facts, 1-11. https://doi.org/10.1159/000551805

Vancouver

Reges O, Abu Ahmad W, Oz-Ramot N, Battat E, Greenland P, Arbel R, et al. Initiation of GLP-1 Receptor Agonists Treatment after Bariatric Metabolic Surgery and Major Adverse Cardiac Events. Obesity Facts. 2026:1-11. doi:10.1159/000551805

BibTeX
@article{Reges2026,
  author = {Reges, Orna and Abu Ahmad, Wiessam and Oz-Ramot, Noga and Battat, Erez and Greenland, Philip and Arbel, Ronen and Wolff Sagy, Yael and Lavie, Gil and Dicker, Dror},
  title = {Initiation of GLP-1 Receptor Agonists Treatment after Bariatric Metabolic Surgery and Major Adverse Cardiac Events},
  journal = {Obesity Facts},
  year = {2026},
  pages = {1--11},
  doi = {10.1159/000551805}
}
Kostenlos starten →